Skip to content

Integra LifeSciences IART Specialty Surgery — R&D

Other segment segments

Tissue Reconstruction
$7.53M

Similar metrics at other companies

Amneal Pharmaceuticals, Inc. logo
AMRXSpecialty — Research And Development Expense
$5.1M-43.7%
Amneal Pharmaceuticals, Inc. logo
AMRXSpecialty — R&D
$5.1M-43.7%
Bausch + Lomb logo
BLCOSurgical — R&D
$13M+18.2%
Thermo Fisher Scientific logo
TMOSpecialty Diagnostics — Research and development expenses
$44M-2.2%
Haemonetics logo
HAEHospital — R&D
$8.46M-6.2%
Chemours logo
CCThermal And Specialized Solutions — Research And Development Expense
$7M0.0%

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's specialty surgery — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's specialty surgery — R&D?
Integra LifeSciences (IART) reported specialty surgery — R&D of $11.85M in Q1 2026.
What does specialty surgery — R&D mean?
This metric captures the investment allocated to innovation, clinical trials, and the development of new surgical technologies within the Specialty Surgery segment. It serves as a key indicator of the company's commitment to long-term product pipeline growth and future competitive advantage.